A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy

This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.

Inclusion:

• Unresectable or metastatic pancreas cancer; participants with previous radical surgery for pancreas cancer are eligible after progression is documented
• Participants may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreas cancer
• ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2
• Adequate organ function
• Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment
• Ability to perform the indicated functional performance measures at baseline

Exclusion:

• Prior systemic therapy for unresectable/metastatic pancreas cancer
• Any medical or psychiatric condition, orthopedic or neuromuscular conditions that could limit participation or confound study results
• Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)